These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

165 related items for PubMed ID: 15843279

  • 1. Cost-efficacy of imatinib versus allogeneic bone marrow transplantation with a matched unrelated donor in the treatment of chronic myelogenous leukemia: a decision-analytic approach.
    Skrepnek GH, Ballard EE.
    Pharmacotherapy; 2005 Mar; 25(3):325-34. PubMed ID: 15843279
    [Abstract] [Full Text] [Related]

  • 2. Cost utility of allogeneic stem cell transplantation with matched unrelated donor versus treatment with imatinib for adult patients with newly diagnosed chronic myeloid leukaemia.
    Breitscheidel L.
    J Med Econ; 2008 Mar; 11(4):571-84. PubMed ID: 19450068
    [Abstract] [Full Text] [Related]

  • 3. Cost-utility analysis of imatinib mesylate for the treatment of chronic myelogenous leukemia in the chronic phase.
    Warren E, Ward S, Gordois A, Scuffham P.
    Clin Ther; 2004 Nov; 26(11):1924-33. PubMed ID: 15639704
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Is imatinib a cost-effective treatment for newly diagnosed chronic myeloid leukemia patients?
    Goldman J.
    Nat Clin Pract Oncol; 2005 Mar; 2(3):126-7. PubMed ID: 16264901
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Targeted agents for chronic myelogenous leukemia: will that be the end of allogeneic bone marrow transplantation for that disease?
    Liang Y, Lai Y, Schwarzenberger P, Li Q, Ma J, Luo J, Liu R, Shi L, Zhou J, Peng Z, Yang J, Deng D, Zhou Y.
    Biol Blood Marrow Transplant; 2010 Jun; 16(6):848-53. PubMed ID: 20138227
    [Abstract] [Full Text] [Related]

  • 10. Occurrence of AML in cells of donor origin after treatment of CML in relapse with imatinib and donor stem cell boost 16 years after the original allogeneic BMT.
    Ditschkowski M, Haferlach C, Schulte C, Trenschel R, Beelen DW.
    Bone Marrow Transplant; 2009 Aug; 44(4):265-6. PubMed ID: 19234516
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Treatment of CML in pediatric patients: should imatinib mesylate (STI-571, Gleevec) or allogeneic hematopoietic cell transplant be front-line therapy?
    Pulsipher MA.
    Pediatr Blood Cancer; 2004 Oct; 43(5):523-33. PubMed ID: 15382266
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. [A case of chronic myelogenous leukemia responding to imatinib mesilate (Glivec) after relapse of blastic crisis following allogeneic bone marrow transplantation].
    Fujisawa S, Yano K, Kobayashi M.
    Gan To Kagaku Ryoho; 2003 Mar; 30(3):427-30. PubMed ID: 12669406
    [Abstract] [Full Text] [Related]

  • 15. [Monitoring bcr/abl mRNA levels in imatinib mesylate treated chronic myeloid leukemia patients by real-time quantitative RT-PCR].
    Qin YZ, Ruan GR, Liu YR, Li JL, Fu JY, Wang H, Chang Y, Jiang B, Jiang Q, Jiang H, Qiu JY, Chen SS, Lu DP.
    Zhonghua Xue Ye Xue Za Zhi; 2005 Jan; 26(1):1-5. PubMed ID: 15946498
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Sustained complete molecular remissions after treatment with imatinib-mesylate in patients with failure after allogeneic stem cell transplantation for chronic myelogenous leukemia: results of a prospective phase II open-label multicenter study.
    Hess G, Bunjes D, Siegert W, Schwerdtfeger R, Ledderose G, Wassmann B, Kobbe G, Bornhäuser M, Hochhaus A, Ullmann AJ, Kindler T, Haus U, Gschaidmeier H, Huber C, Fischer T.
    J Clin Oncol; 2005 Oct 20; 23(30):7583-93. PubMed ID: 16234522
    [Abstract] [Full Text] [Related]

  • 18. Systematic assessment of decision-analytic models for chronic myeloid leukemia.
    Rochau U, Schwarzer R, Jahn B, Sroczynski G, Kluibenschaedl M, Wolf D, Radich J, Brixner D, Gastl G, Siebert U.
    Appl Health Econ Health Policy; 2014 Apr 20; 12(2):103-15. PubMed ID: 24385259
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.